RT Journal Article
SR Electronic
T1 Analysis of SARS-CoV-2 variants from 24,181 patients exemplifies the role of globalisation and zoonosis in pandemics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.10.21262922
DO 10.1101/2021.09.10.21262922
A1 Philippe Colson
A1 Pierre-Edouard Fournier
A1 Hervé Chaudet
A1 Jérémy Delerce
A1 Audrey Giraud-Gatineau
A1 Linda Houhamdi
A1 Claudia Andrieu
A1 Ludivine Brechard
A1 Marielle Bedotto
A1 Elsa Prudent
A1 Céline Gazin
A1 Mamadou Beye
A1 Emilie Burel
A1 Pierre Dudouet
A1 Hervé Tissot-Dupont
A1 Philippe Gautret
A1 Jean-Christophe Lagier
A1 Matthieu Million
A1 Philippe Brouqui
A1 Philippe Parola
A1 Michel Drancourt
A1 Bernard La Scola
A1 Anthony Levasseur
A1 Didier Raoult
YR 2021
UL http://medrxiv.org/content/early/2021/09/12/2021.09.10.21262922.abstract
AB After the end of the first epidemic episode of SARS-CoV-2 infections, as cases began to rise again during the summer of 2020, we at IHU Méditerranée Infection in Marseille, France, intensified the genomic surveillance of SARS-CoV-2, and described the first viral variants. In this study, we compared the incidence curves of SARS-CoV-2-associated deaths in different countries and reported the classification of SARS-CoV-2 variants detected in our institute, as well as the kinetics and sources of the infections. We used mortality collected from a COVID-19 data repository for 221 countries. Viral variants were defined based on ≥5 hallmark mutations shared by ≥30 genomes. SARS-CoV-2 genotype was determined for 24,181 patients using next-generation genome and gene sequencing (in 47% and 11% of cases, respectively) or variant-specific qPCR (in 42% of cases). Sixteen variants were identified by analysing viral genomes from 9,788 SARS-CoV-2-diagnosed patients. Our data show that since the first SARS-CoV-2 epidemic episode in Marseille, importation through travel from abroad was documented for seven of the new variants. In addition, for the B.1.160 variant of Pangolin classification (a.k.a. Marseille-4), we suspect transmission from mink farms. In conclusion, we observed that the successive epidemic peaks of SARS-CoV-2 infections are not linked to rebounds of viral genotypes that are already present but to newly-introduced variants. We thus suggest that border control is the best mean of combating this type of introduction, and that intensive control of mink farms is also necessary to prevent the emergence of new variants generated in this animal reservoir.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the French Government under the Investments for the Future programme managed by the National Agency for Research (ANR), Mediterranee-Infection 10-IAHU-03 and was also supported by Region Provence Alpes Cote d Azur and European funding PRIMMI (Plateformes de Recherche et d'Innovation Mutualisees Mediterranee Infection), FEDER PA 0000320 PRIMMI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of the University Hospital Institute Mediterranee Infection under No. 2020-016-3All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 genome sequences have been submitted to the GISAID sequence database (https://www.gisaid.org/).